Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Columnist Ray Burow, grieving the loss of her dear friend Richard Allen Farmer, reflects on how he cared for her mother, who ...

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

Experimental treatments being developed to address the underlying cause of Alzheimer’s disease mostly target beta-amyloid plaques and tau protein tangles, which are thought to be the main players in ...

For Alzheimer's Awareness Month this November, supporters are encouraged to wear teal and spread the word on social media to educate others.

November is National Alzheimer’s Awareness Month, and the Alzheimer’s Foundation of America (AFA) is encouraging those impacted by Alzheimer’s disease — and their supporters — to wear teal and spread ...

Alzamend Neuro has determined the dosage of AL001, its lithium therapy for Alzheimer’s disease, that will be used in future ...

Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in ...